Clinical trials: Monoclonal
Advanced Cholangiocarcinoma
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma
The study is a phase II clinical trial of single arm. The purpose is to evaluate the safety and efficacy of anti-PD-1 antibody Toripalimab combined with chemotherapy(gemcitabine+5-fluorine pyrimidine) in unresectable advanced…
- Trial name
- NCT03982680
- Testing
- Toripalimab, Gemcitabine, 5- fluorine pyrimidine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangmen Central Hospital
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01302860
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Rheumatoid Arthritis
Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection
This study compares the similarity of the proportion of subjects who achieved ACR20 at week 30 in the two groups.
- Trial name
- NCT04178850
- Testing
- GB242, Infliximab
- Where
- China
- Volunteers
- 568 people
- Sponsor
- Genor Biopharma Co., Ltd.
Mucosal Melanoma
The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery
This is a phase II randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb for injection compared to high-Dose interferon in patients with mucosal melanoma that has been removed by surgery.
- Trial name
- NCT03178123
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab, high-dose recombinant interferon a-2B
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Lymphoma, Malignant Solid Neoplasm
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated blood clots (thrombosis) in patients with cancer receiving chemotherapy.
- Conditions
- Lymphoma, Malignant Solid Neoplasm, Plasma Cell Myeloma
- Trial name
- NCT04465760
- Testing
- Xisomab 3G3
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- OHSU Knight Cancer Institute
Malaria,Falciparum
Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
Mali faces a significant challenge with malaria, particularly among its younger population. While existing measures like seasonal chemoprevention and vaccination have shown efficacy, further innovations are necessary to combat…
- Trial name
- NCT06413108
- Testing
- TB31F, Normal saline
- Where
- Mali
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Safety and Efficacy
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4 aGVHD is systemic glucocorticoid.
- Trial name
- NCT05021276
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Rheumatoid Arthritis
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid…
- Trial name
- GO-FORWARD (NCT00264550)
- Testing
- Golimumab 100 mg, Golimumab 50 mg, Methotrexate
- Where
- 50 sites in United States, Argentina and 10 more
- Volunteers
- 444 people
- Sponsor
- Centocor, Inc.
Phase 1, Dengue
Safety Study of Dengushield in Healthy Adults
This Phase 1 study to evaluate the safety of a single dose of Dengushield (dengue monoclonal antibody) in healthy adults.
- Trial name
- NCT03883620
- Testing
- Dengushield 1 mg/kg (Cohort 1) intravenous, Dengushield 3 mg/kg (Cohort 2) intravenous, Dengushield 7 mg/kg (Cohort 3) intravenous
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Asthma
Study to Evaluate the Safety and Efficacy of CAT-354
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled…
- Trial name
- NCT00873860
- Testing
- CAT-354 150 mg, CAT-354 300 mg, CAT-354 600 mg
- Where
- 57 sites in Bulgaria, Germany and 3 more
- Volunteers
- 357 people
- Sponsor
- MedImmune LLC
Nasopharyngeal Carcinoma
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
This exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and…
- Trial name
- NCT07555860
- Testing
- Becotatug Vedotin, Toripalimab, Camrelizumab
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Non-Hodgkin Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies.
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
- Trial name
- NCT04739813
- Testing
- obinutuzumab, prednisone, Revlimid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD).
- Trial name
- BLISSc-ILD (NCT05878717)
- Testing
- Belimumab
- Where
- 134 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS)
Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 in Blood Samples
the main objectives are 1. to study the pathophysiological role of KIR3DL2 in axSpA and its relationship with Th17 immunity in HLA-B27 + and HLA-B27- patients and 2.
- Trial name
- KIR3DL2 (NCT03322618)
- Testing
- blood samples
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
IgA Nephropathy, IgAN
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
- Trial name
- NCT05125068
- Testing
- AT-1501
- Where
- 26 sites in Australia, Croatia and 8 more
- Volunteers
- 24 people
- Sponsor
- Eledon Pharmaceuticals
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
This phase I trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05135650
- Testing
- Questionnaire Administration, Sotrovimab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Colorectal Cancer
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented…
- Trial name
- NCT02965417
- Testing
- Sym004
- Sponsor
- Symphogen A/S
Leukemia, Lymphoma
PS-341 in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
- Trial name
- NCT00006362
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.